BMS Focuses On Driving Future Growth As Revlimid Generic Launches Near
Opdivo, Eliquis Rise From Year-Ago Quarter, But Down From Q2
New product sales doubled from $161m in the first quarter to $344m in Q3 and the R&D pipeline advancing as planned ahead of generic competition for Revlimid, which will begin to launch in 2022.
You may also be interested in...
As CAR-T Therapies Move Into Earlier Lines, Best Uses Begin To Come Into Focus
Cost, logistics and safety could limit use of CAR-T therapies in first- and second-line treatment of hematologic malignancies, but for some patients there are clear benefits over standards of care.
Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti
Janssen priced the one-time autologous treatment at $465,000, well above the $419,500 list price for Bristol’s first-to-market CAR-T, but expects broad commercial and Medicare coverage.
Bristol’s Bold Projections Grow Bolder As Confidence In R&D Programs Rises
Loss of exclusivity for key Bristol Myers Squibb products, starting with top seller Revlimid, is looming over the company’s R&D pipeline. BMS believes its late-stage and newly approved products will generate more than $25bn in sales by 2029.